Full Press Release Details
| Press Release | Media contact | |
| Christine Peters | ||
| T +49 160 6066 770 | ||
| christine.peters@freseniusmedicalcare.com |
| Contact for analysts and investors | ||
| Dr. Dominik Heger | ||
| T +49 6172 609-2601 | ||
| dominik.heger@freseniusmedicalcare.com | ||
| www.freseniusmedicalcare.com |
Fresenius Medical Care published form 20-F for the fiscal year 2023
Fresenius Medical Care, the world's leading
provider of products and services for individuals with renal diseases, has filed the annual report 2023 on form 20-F with the U.S. Securities
and Exchange Commission (SEC). The report is available at the company's website (www.freseniusmedicalcare.com) in the "Investors"
section as well as at the SEC's website (www.sec.gov).
A hard copy of Fresenius Medical Care's
annual report on form 20-F including the complete audited consolidated financial statements may be obtained from the Company free of
charge upon request to the company's Investor Relations department by email at ir@freseniusmedicalcare.com.
Fresenius Medical Care is the world's leading
provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo
dialysis treatment. Through its network of 3,925 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 333,000
patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's
website at www.freseniusmedicalcare.com.
This release contains forward-looking statements
that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation
or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical
Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility
to update the forward-looking statements in this release.
Implementation of measures as presented herein
may be subject to information and consultation procedures with works councils and other employee representative bodies, as per local laws
and practice. Consultation procedures may lead to changes on proposed measures.